Literature DB >> 8673995

Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy.

R D Marsh1, N M Chu, J N Vauthey, W M Mendenhall, G Y Lauwers, C Bewsher, E M Copeland.   

Abstract

BACKGROUND: This study was designed to determine the efficacy and maximally tolerated dose of 5-fluorouracil when administered by chronobiologically shaped prolonged infusion in combination with radiation therapy in patients with both locally advanced and unresectable rectal carcinoma.
METHODS: Eighteen sequential patients determined clinically to have either locally advanced or unresectable rectal carcinoma were treated by 4500 centigray (cGy) or 5580 cGy, respectively, combined with continuous chronobiologically modulated 5-FU infusion starting at 250 mg/m2/day, with the dose escalating in each cohort of 5 patients if no Grade 3 or higher toxicity was observed in each cohort. Imaging studies were obtained prior to and after completion of treatment.
RESULTS: All 18 patients completed the full course of radiation therapy and all were subsequently resectable for potential cure. The maximum tolerated dose of 5-FU was 275/m2/day for 5 weeks. Seven patients had a sphincter-sparing procedure, and ten patients underwent an abdominoperineal resection, all with clear margins. Five complete pathologic responses (28%) were obtained. The average follow-up time was 12 months with a range of 6 to 37 months. With the exception of two patients, one of whom declined surgery and one of whom died of widespread disease, all of the patients have remained free of disease.
CONCLUSIONS: The combination of radiation therapy and continuous chronobiologically shaped 5-FU infusion at a dose of up to 275/m2/day is well tolerated and appears to be more effective in downsizing and possibly downstaging locally advanced and unresectable rectal carcinoma than radiation therapy alone. Longer follow-up will determine whether ultimate disease free and overall survival are improved by this method.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8673995     DOI: 10.1002/(SICI)1097-0142(19960715)78:2<217::AID-CNCR5>3.0.CO;2-I

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  [Oncology '96].

Authors:  F Hartmann; M Pfreundschuh
Journal:  Med Klin (Munich)       Date:  1997-02-15

Review 2.  Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer.

Authors:  Rolf Sauer
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

3.  Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen).

Authors:  Xin Wang; Yongsheng Wang; Meng Qiu; Qiu Li; Zhi-ping Li; Bing He; Feng Xu; Ya-li Shen; Hong-feng Gou; Yu Yang; Dan Cao; Cheng Yi; Ji-yan Liu; De-yun Luo; Zheng-yin Liao; Feng Bi
Journal:  Med Oncol       Date:  2010-11-30       Impact factor: 3.064

4.  Recent advances in the treatment and outcome of locally advanced rectal cancer.

Authors:  J N Vauthey; R W Marsh; R A Zlotecki; E K Abdalla; C C Solorzano; E J Bray; M E Freeman; G Y Lauwers; P S Kubilis; W M Mendenhall; E M Copeland
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

5.  Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Cem Terzi; Aras Emre Canda; Ozgul Sagol; Koray Atila; Devrim Sonmez; Mehmet Fuzun; Ilknur B Gorken; Ilhan Oztop; Funda Obuz
Journal:  Int J Colorectal Dis       Date:  2007-09-06       Impact factor: 2.571

Review 6.  [Indications for neoadjuvant therapy in rectal carcinoma].

Authors:  F Zimmermann; M Molls
Journal:  Chirurg       Date:  2003-10       Impact factor: 0.955

Review 7.  Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review.

Authors:  M W Saif; Shahrukh Hashmi; Daniel Zelterman; Khaldoun Almhanna; Richard Kim
Journal:  Int J Colorectal Dis       Date:  2007-10-02       Impact factor: 2.571

Review 8.  [Adjuvant and neoadjuvant therapy of rectal carcinoma. The current status].

Authors:  C Rödel; W Hohenberger; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-10       Impact factor: 3.621

9.  Neoadjuvant hyperfractionated accelerated radiotherapy plus concomitant 5-fluorouracil infusion in locally advanced rectal cancer: A phase II study.

Authors:  Zeynep Gural; Sezer Saglam; Serap Yucel; Esra Kaytan-Saglam; Oktar Asoglu; Cetin Ordu; Hediye Acun; Rasul Sharifov; Semen Onder; Ahmet Kizir; Ethem N Oral
Journal:  World J Gastrointest Oncol       Date:  2018-01-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.